Supplementary Material for: GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-analysis of Incidence, Risk, Subtypes, and Mechanisms

GLP-1 receptor agonists (GLP-1 RAs) are linked to a 40% increased risk of non-scarring alopecia, with significant associations found for telogen effluvium and androgenetic alopecia over 12 months. This systematic review and meta-analysis included 17 studies with 1,091,743 patient-exposures. The increased risk is primarily due to weight loss-induced micronutrient deficiency. Notably, semaglutide and tirzepatide showed the highest pharmacovigilance signals. Interestingly, 58% of patients with central centrifugal cicatricial alopecia experienced improvement. Dermatologists are advised to counsel patients on these risks and avoid premature discontinuation of GLP-1 RAs.